From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody-Drug Conjugates. (PubMed, Int J Mol Sci) - Oct 17, 2026 - "Clinically, izalontamab brengitecan supports the feasibility of selected architectures, whereas MEDI4276 and TQB2102 illustrate how complete molecular design shapes therapeutic index. We propose an integrated translational framework and functional design parsimony, defined as selecting the least complex ADC architecture capable of achieving the intended biological and translational objective. Bispecificity should be used only when it provides a demonstrable advantage over a simpler ADC design."
Journal • Review • Oncology
|